Welcome to our dedicated page for Core Scientific, Inc./tx SEC filings (Ticker: CORZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Scientific, Inc./tx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Scientific, Inc./tx's regulatory disclosures and financial reporting.
Pentwater Capital Management LP and Matthew Halbower report beneficial ownership of Core Scientific, Inc. common stock on a Schedule 13G/A. They collectively report 1,336,594 shares of Common Stock, including 800,000 shares issuable upon exercise of options, representing 0.4% of the class based on 317,885,292 shares outstanding as of May 1, 2026. All voting and dispositive authority over these shares is reported as shared, with no sole voting or dispositive power.
Jericho Capital Asset Management L.P. and Josh Resnick report beneficial ownership of Core Scientific, Inc. common stock. They collectively hold 22,882,942 shares of common stock, representing 7.2% of the class.
Both reporting persons have shared voting power over 22,882,942 shares and shared dispositive power over 22,882,942 shares, with no sole voting or dispositive power. Jericho Capital Asset Management L.P. acts as investment adviser to certain investment funds and accounts that have the right to receive or direct dividends and sale proceeds from these shares. Josh Resnick is identified as a reporting person and managing member associated with the adviser. The reporting persons have entered into a joint filing agreement covering this ownership report.
Core Scientific, Inc. has a significant shareholder position reported by Valiant Capital entities and Christopher R. Hansen in an amended Schedule 13G filing. Valiant Capital Management, L.P., Valiant Capital Management, LLC, and Hansen each report beneficial ownership of 16,956,009 shares of Core Scientific common stock, representing 5.3% of the class, based on 321,340,441 shares outstanding as of July 23, 2026.
The shares are held by private investment funds advised by Valiant, which have the right to receive dividends and sale proceeds. Voting and dispositive power over all 16,956,009 shares is reported as shared, with no sole voting or dispositive power. The filers state the securities were not acquired or held for the purpose of changing or influencing control of Core Scientific.
Core Scientific, Inc. completed its previously announced acquisition of Polaris DS LLC, making Polaris a wholly owned subsidiary through a merger with a Core Scientific subsidiary. The company paid an aggregate purchase price of $444.3 million in cash, subject to customary post-closing adjustments, and placed a portion into escrow to secure specified indemnification obligations.
The purchase price may increase by an additional $40 million in cash if an extra 40 megawatts of firm electric capacity becomes available to Polaris before December 31, 2026 under the merger terms. Through the transaction, Core Scientific secured approximately 440 MW of gross, grid-connected power capacity used by Polaris in Oklahoma and reiterated plans to scale its Muskogee campus to about 1.5 GW of gross power, or 1.0 GW of leasable power, with roughly 82 MW expected to be delivered to a customer beginning in the second half of 2027.
Core Scientific, Inc. received an amended Schedule 13G report from Jane Street entities regarding holdings of its common stock, par value $0.00001 per share. As of June 30, 2026, Jane Street Group, LLC reported beneficial ownership of 20,125,585 Core Scientific shares, representing 6.3% of the outstanding common stock.
All reported shares are held with shared voting and shared dispositive power, and no shares are held with sole voting or dispositive power. Within the group, Jane Street Capital, LLC reported 18,771,563 shares (5.9% of the class), Jane Street Global Trading, LLC reported 1,354,018 shares (0.4%), and Jane Street Singapore Pte. Ltd. reported 4 shares. Jane Street Group, LLC files as the parent holding company for these subsidiaries.
Core Scientific, Inc. officer Todd M. Duchene, Chief Legal and Administrative Officer, reported open-market sales of company common stock. On August 10, 2026, he sold 9,000 shares at a weighted average price of $19.8986 per share and 1,000 shares at a weighted average price of $20.6480 per share. The filing states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025, and that the prices reflect multiple trades within disclosed ranges.
Kenneth Griffin and affiliated Citadel entities report a significant passive ownership stake in Core Scientific, Inc. Mr. Griffin may be deemed to beneficially own 20,850,479 Shares of Core Scientific common stock, representing 6.5% of the outstanding Shares.
Citadel Securities LLC may be deemed to beneficially own 12,122,241 Shares (3.8%), and Citadel Securities Group LP and Citadel Securities GP LLC each may be deemed to beneficially own 15,649,788 Shares (4.9%). Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 5,200,691 Shares (1.6%). All reporting persons report no sole voting or dispositive power, but shared voting and dispositive power over their respective blocks. The ownership percentages are based on 321,341,430 Shares outstanding, including 989 Shares issuable upon conversion of certain warrants.
Core Scientific, Inc. reported that Chief Legal and Administrative Officer Todd M. Duchene sold a total of 10,000 shares of common stock on August 3, 2026. The sales occurred in three open market or private transactions at weighted-average prices of $20.3903, $21.55 and $22.6166 per share. All trades were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, with individual sales taking place within price ranges of $19.99–$20.72, $21.03–$21.95 and $22.12–$22.95 per share.
Core Scientific, Inc. shareholder group including Situational Awareness entities, SAF AI GP, Situational Awareness LLC, Situational Awareness Partners, Leopold Aschenbrenner and Carl Shulman reports beneficial ownership of 14,089,395 shares of common stock, representing 4.4% of the class as of the close of business on August 4, 2026.
They previously may have been deemed to beneficially own 25,608,473 shares, or 8.1% of outstanding common stock, as of July 15, 2026. Percentages are based on 321,340,441 shares outstanding as of July 23, 2026 and 317,885,292 shares outstanding as of May 1, 2026. All reporting persons have shared voting and dispositive power over the reported shares, with no sole voting or dispositive power disclosed.
Adams Mark reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that director Mark Adams received a grant of 27,594 restricted stock units of common stock on July 30, 2026. These RSUs vest in two equal installments on July 30, 2027 and July 30, 2028, contingent on his continued service, resulting in direct ownership of 27,594 units.